39919-65-8

Basic information

• Product Name: 2,5-DIBROMO-6-METHYLPYRIDINE
• Synonyms: 2,5-DIBROMO-6-METHYLPYRIDINE;2,5-DIBROMO-6-PICOLINE;2,5-Dibromo-6-methylpyridine 98%;2,5-Dibromo-6-methylpyridine98%;3,6-Dibromo-2-picoline;3,6-Dibromo-2-methylpyridine 98%;Pyridine,3,6-dibroMo-2-Methyl-;3,6-DibroMo-2-Methylpyridine, 97+%
• CAS NO: 39919-65-8
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 250.92
• Product Categories: compounds of pyridine;Pyridine;C6Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines;Heterocycle-Pyridine series;Pyrrolidines
• Mol File: 39919-65-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 0°C
• Boiling Point: 0°C
• Flash Point: 0°C
• Appearance: /
• Density: 1.911 g/cm³
• Vapor Pressure: 0.0488mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: soluble in Methanol
• PKA: -0.84±0.10(Predicted)
• CAS DataBase Reference: 2,5-DIBROMO-6-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIBROMO-6-METHYLPYRIDINE(39919-65-8)
• EPA Substance Registry System: 2,5-DIBROMO-6-METHYLPYRIDINE(39919-65-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-41-22
• Safety Statements: 26-36/37/39
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: III
• Hazardous Substances Data: 39919-65-8(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow solid

InChI:InChI=1/C6H5Br2N/c1-4-5(7)2-3-6(8)9-4/h2-3H,1H3

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 54923-31-8 5-bromo-2-hydroxy-6-methylpyridine 
• 42753-71-9 5-bromo-6-methyl-pyridin-2-ylamine 
• 853569-71-8 5-bromo-2-amino-6-picoline hydrobromide 

Downstream Products

• 1008361-77-0 3-bromo-6-iodo-2-methylpyridine 
• 137778-18-8 5-bromo-6-methyl-pyridine-2-carbaldehyde 
• 126717-59-7 3-bromo-6-methoxy-2-methylpyridine 
• 1173897-86-3 5-bromo-6-methylpyridine-2-carbonitrile 

Relevant articles and documents

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against mycobacterium tuberculosis

DNA gyrase is a clinically validated target for developing drugs against Mycobacterium tuberculosis (Mtb). Despite the promise of fluoroquinolones (FQs) as anti-tuberculosis drugs, the prevalence of pre-existing resistance to FQs is likely to restrict their clinical value. We describe a novel class of N-linked aminopiperidinyl alkyl quinolones and naphthyridones that kills Mtb by inhibiting the DNA gyrase activity. The mechanism of inhibition of DNA gyrase was distinct from the fluoroquinolones, as shown by their ability to inhibit the growth of fluoroquinolone-resistant Mtb. Biochemical studies demonstrated this class to exert its action via single-strand cleavage rather than double-strand cleavage, as seen with fluoroquinolones. The compounds are highly bactericidal against extracellular as well as intracellular Mtb. Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability. Compounds from this series are efficacious in various murine models of tuberculosis.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

NOVEL TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION

This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula (I): Wherein R1, R2, R3, R4, and R5are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.